Immuno-Oncology | Specialty

Dr. Alter Discusses Provenge MOA and Tolerability

December 2nd 2011

Dr. Robert Alter from John Theurer Cancer Center Discusses Provenge MOA and Tolerability

Dr. Alter Discusses the Provenge Treatment Process

November 17th 2011

Dr. Robert Alter from John Theurer Cancer Center Discusses the Provenge Treatment Process

Dr. Alter Discusses the Immunotherapy Provenge

November 11th 2011

Dr. Robert Alter from John Theurer Cancer Center Discusses the Immunotherapy Provenge

Value-Based Coverage Decisions: CMS Scrutinizes Provenge

August 25th 2011

In late March, CMS ended the speculation by announcing its intention to pay for onlabel uses of the drug, which costs $93,000 for a 3-dose regimen, while leaving off-label coverage decisions to its regional contractors.

Dr. Hoos Discusses the Next Steps for Ipilimumab

August 9th 2011

Dr. Axel Hoos medical lead at Bristol-Myers Squibb Discusses the Next Steps for Ipilimumab

Dr. Hoos Discusses Patients Eligible to Receive Ipilimumab

August 3rd 2011

Dr. Axel Hoos medical lead at Bristol-Myers Squibb Discusses Which Patients are Eligible to Receive Ipilimumab

Dr. Hoos on the Ipilimumab Plus Dacarbazine Trial

July 29th 2011

Dr. Axel Hoos medical lead at bristol-myers squibb on the Ipilimumab Plus Dacarbazine Combination Trial

Dr. Hoos on Why Melanoma is Amenable to Immunotherapy

July 26th 2011

Dr. Axel Hoos medical lead at Bristol-Myers Squibb on Why Melanoma is Amenable to Immunotherapy

Dr. Hoos Explains the Future of Immunotherapy

July 18th 2011

Dr. Axel Hoos from Bristol-Myers Squibb Explains the Future of Immunotherapy and Ipilimumab's role

Aiming for Immunity: New Therapies in Sights

July 14th 2011

Even before the FDA approved ipilimumab in March, the field of cancer immunotherapy was a lively area of scientific inquiry.

Dr. Schuchter on Managing Ipilimumab's Side Effects

July 13th 2011

Dr. Lynn Schuchter from Penn Medicine Discusses Managing Ipilimumab's (Yervoy) Side Effects with the REMS program

Dr. Hoos Describes Ipilimumab and Future Immunotherapies

July 13th 2011

Dr. Axel Hoos medical lead from Bristol-Myers Squibb Describes Ipilimumab and Future Immunotherapies

Dr. Hoos on Tools Available to Measure Ipilimumab's Success

July 7th 2011

Dr. Axel Hoos from Bristol Myers-Squibb on Tools Available to Measure Ipilimumab's Success

Dr. Hoos Discusses the Clinical Kinetics of Immunotherapy

July 1st 2011

Dr. Axel Hoos the medical lead in Immunology/Oncology at Bristol-Myers Squibb Discusses the Clinical Kinetics of Immunotherapy

Dr. Hoos on a Possible Successor Drug to Ipilimumab

June 22nd 2011

Dr. Axel Hoos Medical Lead in Immunology/Oncology at Bristol-Myers Squibb on a Possible Successor Drug to Ipilimumab

Dr. Wolchok on Patients That Had to Stop Treatment Early

June 20th 2011

Dr. Jedd D. Wolchok From Memorial Sloan-Kettering Cancer Center on Patients That Had to Stop Treatment Early

Dr. Wolchok Explains the Future of Ipilimumab

June 17th 2011

Dr. Wolchok From Memorial Sloan-Kettering Cancer Center Explains the Future of Ipilimumab

Dr. Wolchok Describes Candidates for Ipilimumab

June 16th 2011

Dr. Wolchok from Memorial Sloan-Kettering Cancer Center Describes Candidates for Ipilimumab

Dr. Hoos Discusses Key Points of the Ipilimumab Trial

June 15th 2011

Dr. Hoos From Bristol-Myers Squibb Discusses Key Points of the Ipilimumab Trial

Immunotherapies: Avoiding Collisions Once the Brake Is Released

June 11th 2011

Immunotherapies made headlines in oncology last month when the Centers for Medicare & Medicaid Services (CMS) decided that the anticancer vaccine sipuleucel-T (Provenge) will be a payable expense for prostate cancer.